{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiefn7lz6bucpdbcbxnpholplwxgnnemj7q3lg2uhkfzwis2tf725m",
    "uri": "at://did:plc:k7h5fn3kdhjpj37pc6yhno2o/app.bsky.feed.post/3meaxev7ctyr2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibrxfe57eixwhc6o45r57m2lh3dxtnaar5tmecx2sy567fdi6jr6m"
    },
    "mimeType": "image/jpeg",
    "size": 81293
  },
  "path": "/article/new-glp-1-weight-loss-drugs-are-coming-and-theyre-stronger-than-wegovy-zepbound/",
  "publishedAt": "2026-02-06T19:15:00.000Z",
  "site": "https://www.scientificamerican.com",
  "textContent": "The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than current treatments. But experts wonder how much is too much",
  "title": "New GLP-1 weight-loss drugs are coming—and they’re stronger than Wegovy and Zepbound"
}